After exploring a mechanistic approach and a tumour type as part of our AACR annual meeting coverage, in our third preview today we turn to look at a novel target.
This particular target hasn’t received much attention at all but this could well change in the future as some of the compounds move into the clinic.
There are a few important questions to consider:
- Who’s going to be first to evaluate in humans?
- Which tumour types will be optimal?
- Which combinations are likely to be synergistic, tolerable and effective?
- What path to market strategies will avoid the enrollment problems now that checkpoint blockade is becoming much more ubiquitous?
This is an interesting niche that may well evolve into a competitive landscape going forward.